

1 **Differential age-specific effects of LDL cholesterol and body mass index on the**
2 **risk of coronary heart disease.**

3 Jun Xiao, M.D., Ph.D^{1,2}, Liangwan Chen, M.D., Ph.D^{1,2}, Weimin Ye, M.D., Ph.D^{3,4*},
4 Wuqing Huang, M.D., Ph.D^{3*}

5 ¹ Department of Cardiovascular Surgery, Fujian Medical University Union Hospital,
6 Fuzhou, Fujian, China.

7 ² Fujian Provincial Clinical Research Center for Cardiovascular Diseases Heart Center
8 of Fujian Medical University, Fuzhou, Fujian, China.

9 ³ Department of Epidemiology and Health Statistics, School of Public Health, Fujian
10 Medical University, Fuzhou, Fujian, China.

11 ⁴ Department of Medical Epidemiology and Biostatistics, Karolinska Institutet,
12 Stockholm, Sweden.

13 **Short title:** LDL cholesterol, BMI and coronary heart disease.

14 ***Share the senior authorship.**

15 **Correspondence:** Wuqing Huang and Weimin Ye

16 Fujian Medical University

17 No 1, Xue Yuan Road, University Town, 350108

18 Fuzhou City, Fujian Province, China.

19 Email: wuqing.huang@fjmu.edu.cn; ywm@fjmu.edu.cn

20 Telephone: +8617338896101

21 **Word count:** abstract(255), text(3349), figures(4), tables(4)

22 **Abbreviations:** BMI, body mass index; CHD, coronary heart disease; LDLc, low-

23 density lipoprotein cholesterol; MetS, metabolic syndrome; MI, myocardial infarction;
24 PERM, percentage of excess risk mediated; RCS, restricted cubic spline; RERI,
25 relative excess risk due to interaction.

26 **Acknowledgments:** This study has been performed using the UK Biobank Resource
27 under Application Number 84352. We thank the subjects and investigators who
28 contributed to the UK Biobank.

29 **Competing interests:** The authors declare no conflict of interest.

30 **Funding Information:** This work was supported by the Natural Science Foundation
31 of Fujian Province (grant no. 2022J01706) and the Start-up Fund for high-level talents
32 of Fujian Medical University (grant no.XRCZX2021026) to Dr. Wuqing Huang, and
33 by the Start-up Fund for high-level talents of Fujian Medical University (grant no.
34 XRCZX2017035 and XRCZX2020034) to Dr. Weimin Ye. The funder had no role in
35 study design, data collection and interpretation, or the decision to submit the work for
36 publication.

37 **Author Contributors:** All authors were responsible for the study concept and design.
38 WH and WY obtained funding. JX did the statistical analysis, JX and WH drafted the
39 manuscript, and all authors revised it for important intellectual content.

40 **Data Sharing Statement**

41 Data from the UK Biobank is available to researchers upon a data access application.

42 **Clinical Perspective**

43 **What Is New?**

- 44 ● This study shows, for the first time, that there were differential age-specific
45 effects of LDLc and BMI on the risk of developing coronary heart disease (CHD),
46 in which the LDLc-CHD association diminished with increasing age while no
47 declining trend was found in BMI-CHD relationship.
- 48 ● The interaction and mediation between LDLc and BMI on the risk of coronary
49 heart disease were only present in young adults.

50 **What Are the Clinical Implications?**

- 51 ● Future efforts are called to discriminate the age-different benefits from lipids
52 management or weight control on the primary prevention for CHD.
- 53 ● Findings from this study highlighted that lipids management at young age was
54 expected to have a much more favorable benefit in CHD prevention; and weight
55 control shouldn't be overlooked, especially for elderly adults, as lipid-lowering
56 therapy might not contribute to the reduction of obesity-related CHD.

57 **Abstract**

58 **Background:** Low-density lipoprotein cholesterol (LDLc) and body mass index (BMI)
59 are not always correlated and their relationship is probably dependent on age,
60 indicating differential age-specific effects of these two factors on health outcomes. We
61 thus aimed to discriminate the effects of LDLc and BMI on the risk of coronary heart
62 disease (CHD) across different age groups.

63 **Methods:** This is a prospective cohort study of 368,274 participants aged 38-73 years
64 and free of CHD at baseline. LDLc and BMI were measured at baseline, and incident
65 CHD was the main outcome. Cox proportional hazards model and restricted cubic
66 spline (RCS) regression were used to estimate hazard ratio (HR) and 95% confidence
67 interval (CI) of exposure on CHD.

68 **Results:** Similar relationships of LDLc and BMI with CHD risk were observed in
69 overall population but in differential age-specific patterns. Across the age groups of
70 <50, 50-54, 55-59, 60-64 and ≥ 65 years, the LDLc-CHD association diminished
71 with the adjusted HRs decreasing from 1.35, 1.26, 1.19, 1.11 to 1.08; while no
72 declining trend was found in BMI-CHD relationship with the adjusted HRs of 1.15,
73 1.11, 1.12, 1.13 and 1.15, respectively. The interaction and mediation between LDLc
74 and BMI on CHD risk were only present at young-age groups. And the LDLc-CHD
75 but not BMI-CHD association was dependent on sex, metabolic syndrome and
76 lipid-lowering drugs use.

77 **Conclusion:** There were differential age-specific effects of LDLc and BMI on the risk
78 of developing CHD, calling for future efforts to discriminate the age-different benefits

79 from lipids management or weight control on the primary prevention for CHD.

80 **Introduction**

81 Population aging leads to an increased incidence of coronary heart disease (CHD).
82 Low-density lipoprotein cholesterol (LDLc) and body mass index (BMI) are
83 well-established determinants of CHD, both of which are complex phenotypes and
84 shared lots of common risk factors. Besides, both obesity and high cholesterol have
85 been involved in “paradox” phenomenon, defined as higher cholesterol or BMI being
86 associated with an elevated incidence of diseases while paradoxically related to a
87 reduced mortality^{1,2}. Thus, it seems plausible to expect similar effects of these two
88 factors on diseases. Nevertheless, emerging evidence found that LDLc and BMI were
89 not always correlated, for example, findings from two large cross-sectional studies
90 found that the association between BMI and LDLc was completely lost in population
91 older than 60 years, indicating that the role of LDLc and BMI in diseases might not
92 always stay in sync and probably varied by age³. A number of studies have
93 investigated the age-specific effect of LDLc on CHD but generated inconsistent
94 results, and the influence of age was poorly demonstrated on the association between
95 BMI and CHD⁴⁻⁹. To date, there is insufficient data discriminating the independent
96 effect of LDLc and BMI on the risk CHD across the lifespan.

97 The high prevalence of hyperlipidemia and obesity, as well as the demographic
98 variation relevant to aging population, call for concerns to clarify the age-specific
99 health effects of LDLc and BMI so as to anticipate benefits that might be achieved via
100 LDLc reduction or weight control at different ages. Hence, in this study, we aimed to
101 explore how the effects of LDLc and BMI on the risk of developing CHD varied from

102 mid-life through late-life. Given of the prior evidence regarding the impact of sex and
103 metabolic disorders in the BMI-LDLc relationship and the known effect of
104 lipid-lowering treatment on CHD, we also performed stratified analyses to explore
105 whether the age-specific associations differ by sex, metabolic syndrome (MetS) and
106 lipid-lowering drug use^{3, 10}.

107 **Methods**

108 **Study design and population**

109 This cohort study was conducted based on UK Biobank project, which recruited more
110 than 500 000 residents aged 38–73 years in 22 assessment centers across the UK¹¹. At
111 the baseline visit between March 2006 and July 2010, participants completed online
112 or/and verbal questionnaires and physical measurements, as well as provided
113 biological sample. The North West Multi-Centre Research Ethics Committee has
114 approved UK Biobank study (REC reference: 21/NW/0157) and all participants
115 signed informed consent.

116 In this study, participants were excluded if they: (1) had a history of CHD before
117 baseline visit, (2) had less than 180 days of follow-up, (3) had missing data of lipids
118 or physical measurements. Finally, a total of 368,274 participants were included for
119 analysis (**Supplementary Figure 1**).

120 **Assessment of exposure and covariates**

121 Weight and height were measured at baseline and BMI was calculated as weight (kg)
122 being divided by height (m) squared. Blood samples were collected at baseline and
123 the levels of serum lipids were measured using the Beckman Coulter AU5800

124 Platform, in which LDLc was measured directly and analyzed via enzymatic selective
125 protection method^{12, 13}. To reduce systematic error, standardized procedures were
126 conducted for each sample following the protocol and Internal Quality Control (IQC)
127 was performed for each assay, details of which have been described elsewhere^{12, 13}.

128 Sociodemographic and lifestyle information were obtained by self-reported
129 questionnaires. Age was calculated as the difference between the date of birth and
130 baseline assessment. Ethnicity was dichotomized as British or not. Education was
131 recorded as six categories and unknown group. Socioeconomic status was measured
132 by the Townsend deprivation index assigned at baseline¹⁴. Smoking status was
133 categorized as never, former smoker, current smoker and unknown status; passive
134 smoking status was dichotomized as yes or not. Alcohol intake frequency was
135 categorized as daily, often (one to four times a week), seldom (one to three times a
136 month or special occasions only), never and unknown. Physical activity was assessed
137 using the International Physical Activity Questionnaire and recorded as summed
138 metabolic equivalent (MET) minutes per week for all activity^{15, 16}. Metabolic
139 disorders, including hypertension, hyperglycemia/diabetes, hypertriglyceridemia and
140 low high-density lipoprotein (HDL) cholesterol, were defined according to the IDF
141 definition by combining information from self-report medical conditions, medications
142 and biochemistry data at baseline (systolic blood pressure \geq 130 mmHg or diastolic
143 blood pressure \geq 85 mmHg; fasting plasma glucose \geq 5.6 mmol/l; triglycerides \geq 1.7
144 mmol/l; HDL cholesterol \leq 1.03 mmol/l in men or \leq 1.29 mmol/l in women)¹⁷. MetS
145 was defined as having central obesity (waist circumference \geq 90 cm in men or \geq 80

146 cm in women) and two or more metabolic disorders mentioned above ¹⁷. Use of
147 lipid-lowering drugs was self-reported in touchscreen questionnaire or verbal
148 interview at baseline.

149 **Assessment of outcomes**

150 The main outcome was incident CHD and the secondary outcome was incident
151 myocardial infarction (MI). CHD was identified by using the International
152 Classification of Disease 10 of I20-I25 from category of “First occurrence” (Category
153 ID: 1712) with Field IDs of 131297, 131299, 131301, 131303, 131305 and 131307.
154 Myocardial infarction was identified by using Field ID of 42001 from category of
155 “Algorithmically-defined outcomes” (Category ID: 42). Fields in both “First
156 occurrence” and “Algorithmically-defined outcomes” categories were derived from
157 self-reported medical conditions, primary health care, hospital admission data and
158 death registry data in the UK Biobank cohort.

159 **Statistical analysis**

160 Baseline characteristics are presented as frequency and percentage for categorical
161 variables and as mean and standard deviation for continuous variables across different
162 age groups (i.e., <50 years, 50-54 years, 55-59 years, 60-64 years, and ≥65 years).
163 Participants were followed up from the date of baseline assessment to the date of the
164 outcome occurrence, the date of death, the date of loss-to-follow, or the censoring date
165 (May 20, 2022), whichever occurred first.

166 We first explored the associations between LDLc, BMI and risk of CHD in
167 different age groups. Restricted cubic spline (RCS) regression was first applied to

168 explore the non-linear relationship by including the exposure as a continuous variable,
169 in which we tried to perform models with different knots and found that there was
170 little change in the shape since four knots, thus RCS regression with four knots was
171 chosen as the main model ¹⁸. Next, Cox proportional hazards model was used to
172 investigate the hazard ratio (HR) and 95% confidence interval (CI) between LDLc,
173 BMI and risk of CHD, in which, based on clinical relevance and previous literature,
174 we modelled LDLc per 1 mmol/L increment as follows: <2, 2-2.9, 3-3.9, 4-4.9, 5-5.9,
175 and ≥ 6 mmol/L; and modelled BMI per class increment using standard categories as
176 follows: underweight (<18.5 kg/m²), healthy weight (18.5-24.9 kg/m²), overweight
177 (25.0-29.9 kg/m²), obesity class 1 (30.0-34.9 kg/m²), obesity class 2 (35.0-39.9 kg/m²),
178 and obesity class 3 (≥ 40 kg/m²) ^{5,19}. Given of the potential impact of competing risk
179 from death, Fine-Gray competing risk model was further performed to examine the
180 association by defining death as a competing event. Stratified analyses were also
181 performed by sex, MetS or lipid-lowering drugs use across different age groups, and
182 heterogeneity between strata was tested by including a product term of the
183 stratification factor and exposure in the model. The models were first adjusted for age
184 at baseline and sex, then in multivariable models additionally for ethnicity, education,
185 smoking, passive smoking, alcohol intake frequency, physical activity, Townsend
186 deprivation index, metabolic disorders, lipid lowering drugs, and body mass index or
187 LDLc.

188 We further evaluated the age-specific mediation and interaction between LDLc
189 and BMI on CHD. Mediation analysis was performed to explore the mediated role of

190 LDLc between BMI and CHD, or the role of BMI between LDLc and CHD, by using
191 the percentage of excess risk mediated (PERM), which was calculated by using the
192 formula of $(HR_{(\text{confounders adjusted})} - HR_{(\text{confounders and mediator adjusted})}) / (HR_{(\text{confounders adjusted})} -$
193 $1)$. Interaction between LDLc and BMI on CHD were assessed in both additive scale
194 and multiplicative scale²⁰. Addictive interaction was measured by relative excess risk
195 due to interaction (RERI), calculated as $HR_{(\text{increased LDLc \& increased BMI})} - HR_{(\text{increased BMI$
196 $\text{alone})} - HR_{(\text{increased LDLc alone})} + 1$, in which LDLc and BMI was dichotomized as
197 increased or not according to the cut-off value of 3.4 mmol/L and 25 kg/m²
198 respectively, and then the population was divided into four groups for analysis (i.e.,
199 neither LDLc nor BMI increased, LDLc increased alone, BMI increased alone and
200 both increased). Multiplicative interaction was identified by the p value of
201 product-term of LDLc and BMI in the multivariable model.

202 All analyses were performed in SAS 9.4 or R 4.1.2 and *P*-value of <0.05 was
203 considered as of statistical significance.

204 **Results**

205 As shown in **Table 1**, a total of 368,274 participants were included in the analyses,
206 consisting of 202,853 (55.1%) females and 165,421 (44.9%) males. The mean age of
207 study population was 57 years, the mean level of LDLc was 3.6 mmol/L and the mean
208 BMI was 27.3 kg/m². After a mean of 12 years of follow-up, 26,947 participants
209 developed CHD with the incidence rate of 5.86 per 1000 person-years, and the
210 incidence rates of CHD continuously increased with increasing age. There were
211 84717, 56544, 65680, 87263, 74070 participants across age groups of <50 years,

212 50-54 years, 55-59 years, 60-64 years, and ≥ 65 years, and the distribution of
213 sociodemographic characteristics, lifestyle, history of metabolic disorders and
214 lipid-lowering drug use were significantly different across age groups.
215 **Supplementary Figure 2** shows that participants with LDLc of 3-3.9 mmol/L or BMI
216 of 25-29.5 kg/m² accounted for the highest proportion across all age groups.

217 As shown in **Figure 1 and Supplementary Figure 3**, RCS regression found near
218 linear relationship between LDLc, BMI and CHD risk, especially when the level of
219 LDLc or BMI was above 3 mmol/L or 25 kg/m². Stratified analyses by age groups
220 observed that the association of LDLc but not BMI with CHD almost diminished with
221 the increasing age (**Figure 2**). Cox proportional hazards model found similar elevated
222 risk of CHD for the overall population per 1 mmol/L increment in LDLc
223 (multivariable adjusted HR: 1.16, 95% CI: 1.14-1.18) and per class increment in BMI
224 (multivariable adjusted HR: 1.14, 95% CI: 1.12-1.16) (**Table 2**). Consistent with
225 findings from RCS regression, stratified analyses in Cox proportional hazards model
226 showed that across the age groups of <50, 50-54, 55-59, 60-64 and ≥ 65 years, the
227 positive association between LDLc and CHD declined along the increasing age with
228 the multivariable adjusted HRs decreasing from 1.35, 1.26, 1.19, 1.11 to 1.08
229 ($P_{\text{heterogeneity}} < 0.001$); however, although there was a significant heterogeneity in
230 BMI-CHD associations across age groups, no declining trend was observed with
231 increasing age, and the multivariable adjusted HRs of which were 1.15, 1.11, 1.12,
232 1.13 and 1.15, respectively (**Figure 3 and Table 2**). Fine-Gray competing risk model
233 showed similar results, suggesting a small role of the competing risk in the observed

234 associations (**Supplementary Table 1**). **Supplementary Table 2** shows the results for
235 MI; similarly, the positive association of LDLc with the risk of MI also declined
236 across the increasing age ($P_{\text{heterogeneity}} < 0.001$) while the relationship between BMI and
237 MI was independent of age ($P_{\text{heterogeneity}} = 0.128$). Although the effect on MI related to
238 per 1 mmol/L higher in LDLc was always greater than that associated with per class
239 higher in BMI across all age groups, the difference in the association of LDLc and
240 BMI with MI was attenuating with increasing age.

241 In **Figure 4 and Supplementary Table 3**, stratified analyses by sex found a
242 significantly stronger LDLc-CHD association ($P_{\text{heterogeneity}}$ for overall population:
243 < 0.001) and a slightly insignificantly stronger BMI-CHD association ($P_{\text{heterogeneity}}$
244 for overall population: 0.405) in males than females across all age groups; irrespective
245 of sex, the LDLc-CHD association declined with increasing age while the BMI-CHD
246 association kept stable. In **Figure 2 and Supplementary Table 4**, stratified analyses
247 by MetS observed a stronger association between LDLc and CHD among individuals
248 without MetS than those with, across all age groups despite without statistical
249 significance in some age groups ($P_{\text{heterogeneity}}$ for overall population: < 0.001),
250 while no significant heterogeneity was found in BMI-CHD association between
251 individuals with and without MetS in most age groups except the age group of
252 younger than 50 years ($P_{\text{heterogeneity}}$ for overall population: 0.346); regardless of
253 MetS, diminished trend was found in LDLc-CHD but not BMI-CHD association with
254 increasing age. In **Figure 2 and Supplementary Table 5**, stratified analyses by
255 lipid-lowering drug use showed significant heterogeneity in LDLc-CHD association

256 between lipid-lowering drug users and non-users, specifically among adults younger
257 than 55 years old (P heterogeneity=0.001); besides, the LDLc-CHD association
258 declined with increasing age in non-users but kept stable in lipid-lowering drug users,
259 while no obvious trend was observed for BMI-CHD association regardless of
260 lipid-lowering drug use or not.

261 Mediation analysis found that LDLc played a mediated role in BMI-CHD
262 association at young ages with the PERM of 11.76% and 8.33% in the age group of
263 <50 years and 50-54 years respectively; the mediated effect of BMI in LDLc-CHD
264 association was only observed in the age group of <50 years with the PERM of 2.78%
265 (**Table 3**). Interaction analysis showed a greater positive additive interaction between
266 BMI and LDLc in younger adults than older ones although no significant
267 multiplicative interaction found throughout all ages; the effect of higher LDLc alone
268 or both higher BMI and LDLc on CHD risk declined with increasing age while no
269 significant trend was found for the effect of higher BMI alone on CHD (**Table 4**).

270 **Discussion**

271 This prospective cohort study found similar independent effects of LDLc and BMI on
272 CHD risk in overall population, while the age-specific associations with CHD risk
273 showed significant different patterns between LDLc and BMI. The LDLc-CHD
274 association declined with increasing age while the BMI-CHD relationship was
275 independent of age. The strongest negative effect of high LDLc on CHD was found in
276 young adults without using lipid-lowering drugs, and the interactive effect between
277 LDLc and lipid-lowering drug use on CHD risk was only observed in adults younger

278 than 55 years. Besides, the interaction and mediation between LDLc and BMI on
279 CHD were only present in young adults. These findings highlighted that lipids
280 management at young age was expected to have a much more favorable benefit in
281 CHD prevention; and weight control shouldn't be overlooked, especially for elderly
282 adults, as lipid-lowering therapy might not contribute to the reduction of
283 obesity-related CHD.

284 Hypercholesterolemia and obesity share some common risk factors and
285 pathophysiologic mechanisms, both of non-negligible importance in the onset of CHD.
286 Although previous literature has found observational and genetic associations
287 between BMI and LDLc, growing evidence suggested that the correlation seemed to
288 be varied by metabolic status linked to aging or metabolic disorders, indicating that
289 the health effect of BMI and LDLc might not always stay consistent^{3, 10, 21, 22}.

290 Age has been reported to play a role in the association of BMI or LDLc with
291 health outcomes^{1, 4-8}. Despite the causal relationship between LDLc and the risk of
292 CHD, the impact of LDLc or the benefit of lipid-lowering therapy on the occurrence
293 of CHD is being challenged in older population^{4-8, 23-25}. Some studies have observed
294 that the positive association of LDLc with incident CHD attenuated or even
295 disappeared in older adults, while a recent contemporary cohort argued that
296 individuals aged 70-100 years with higher LDLc had the highest absolute risk of
297 atherosclerotic cardiovascular disease as compared to other age groups, suggesting the
298 importance of LDLc-lowering treatment for prevention in extremely-elderly
299 population⁴⁻⁸. The net benefit of statins use on primary prevention of atherosclerotic

300 cardiovascular events was also controversial and guidelines regarding the role of
301 statins remained equivocal in older adults²³⁻²⁵. The “obesity paradox” phenomenon
302 has been proposed for decades with respect to the lower mortality in obese adults in
303 older patients¹. Nevertheless, the age-related effect of obesity in the incidence of
304 diseases was rarely clarified, and previous studies found a declining trend in the effect
305 of higher BMI on the occurrence of some diseases, such as dementia, while a cohort
306 study of population aged >60 years found that obesity was independently associated
307 with elevated incidence of CHD in older population, at least to age 84^{9,26}. There is a
308 dearth of data on discrimination of the independent effect of LDLc and BMI on health
309 outcomes across age groups. In the current study, we found similar relationships for
310 both LDLc and BMI with the risk of developing CHD but differential age-specific
311 effects between LDLc and BMI. The excess risk on CHD from higher LDLc
312 attenuated with increasing age while the relationship between BMI and the incidence
313 of CHD kept stable across all age groups, resulting in a greater excess risk associated
314 with per mmol/L higher in LDLc in young adults but a higher excess risk related to
315 per class increase in BMI in adults older than 60 years. Despite declined strength of
316 the LDLc-CHD association in elderly people, the negative health effect of higher
317 LDLc stayed statistically significant. These findings casted doubt on suggestions
318 about guideline revision given of the “obesity paradox” or “cholesterol paradox”
319 phenomenon at older ages but called for future efforts to discriminate the
320 age-different benefits from lipids management or weight control on the primary
321 prevention for CHD.

322 Some studies have investigated the mediated role of LDLc between BMI and
323 CHD, for example, a large pooled analysis found the excess risk of CHD per unit of
324 BMI can be largely explained by metabolic mediators whereas cholesterol explained
325 only additional 5% excess risk; another population-based study found that LDLc
326 explained the excess risk of CHD with 22% excess risk from the observational obesity
327 and 8% excess risk from genetically-determined obesity^{22, 27}. In this study, we
328 extended the knowledge in light of the age-different mediation or interaction between
329 LDLc and BMI on the risk of CHD, and found that the mediated effect of LDLc or
330 BMI between BMI or LDLc and CHD risk was only present in young adults, so did
331 the interaction effect, indicating a greater benefit of lipids management or weight
332 control on preventing CHD at young ages.

333 Difference in the sex- or MetS- specific effects was further observed between
334 LDLc and BMI on CHD risk in this study. A prior cohort study in Korean population
335 demonstrated sex-specific association of MetS (an obesity-driven complex disorder)
336 and LDLc with the incidence of cardiovascular and cerebrovascular disease (CCVD),
337 in which MetS alone was linked with a higher risk of CCVD regardless of sex while
338 the impact of higher LDLc alone on CCVD was more pronounced in men than in
339 women²⁸. Consistently, the current study found that the association of BMI with
340 CHD risk was independent of sex but the effect of high LDLc on CHD was
341 significantly greater in men than in women across all age groups. MetS also seemed
342 to play a role in the LDLc-CHD but not BMI-CHD relationship; the effect of higher
343 LDLc was stronger among people without MetS than those with, which called for

344 more studies in light of the underlying reasons. In addition, stratified analyses by
345 lipid-lowering drug use observed the highest excess risk of CHD related to high LDLc
346 in youngest adults without using lipid-lowering drugs and the absent heterogeneity in
347 the effect of LDLc on CHD between users and non-users in older adults, further
348 suggesting that lipids management should start at earlier ages for the primary
349 prevention of CHD.

350 This study had some strengths. First, this study extended the knowledge
351 regarding the differential age-specific effects of LDLc and BMI on the risk of
352 developing CHD. Second, the large sample size allowed us to explore the associations
353 across age groups per 5-year interval with sufficient statistical power. Third,
354 information of the outcome was obtained by combining several sources to minimize
355 the misclassification of outcome. Fourth, several statistical methods were applied to
356 estimate the associations, contributing to examine the robustness of the results. The
357 major limitation of this study was that the age of this study population ranged from 38
358 to 73, thus not allowing us to explore the relationship in extreme elderly individuals.
359 Besides, most participants in UK Biobank are European, thus findings should be
360 interpreted cautiously in terms of generalization.

361 In conclusion, this study found differential age-specific effects between LDLc
362 and BMI on the risk of developing CHD, calling for future efforts to discriminate the
363 age-different benefits from lipids management or weight control on the primary
364 prevention for CHD.

365

366 **References:**

- 367 1. Wang S and Ren J. Obesity Paradox in Aging: From Prevalence to
368 Pathophysiology. *Progress in cardiovascular diseases*. 2018;61:182-189.
- 369 2. Orkaby AR. The Highs and Lows of Cholesterol: A Paradox of Healthy Aging?
370 *Journal of the American Geriatrics Society*. 2020;68:236-237.
- 371 3. Laclaustra M, Lopez-Garcia E, Civeira F, Garcia-Esquinas E, Graciani A,
372 Guallar-Castillon P, Banegas JR and Rodriguez-Artalejo F. LDL Cholesterol Rises
373 With BMI Only in Lean Individuals: Cross-sectional U.S. and Spanish Representative
374 Data. *Diabetes care*. 2018;41:2195-2201.
- 375 4. Jung HN, Kim MJ, Kim HS, Lee WJ, Min SH, Kim YJ and Jung CH.
376 Age-Related Associations of Low-Density Lipoprotein Cholesterol and
377 Atherosclerotic Cardiovascular Disease: A Nationwide Population-Based Cohort
378 Study. *Journal of the American Heart Association*. 2022;11:e024637.
- 379 5. Mortensen MB and Nordestgaard BG. Elevated LDL cholesterol and increased
380 risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals
381 aged 70-100 years: a contemporary primary prevention cohort. *Lancet (London,*
382 *England)*. 2020;396:1644-1652.
- 383 6. Nanna MG, Navar AM, Wojdyla D and Peterson ED. The Association Between
384 Low-Density Lipoprotein Cholesterol and Incident Atherosclerotic Cardiovascular
385 Disease in Older Adults: Results From the National Institutes of Health Pooled
386 Cohorts. *Journal of the American Geriatrics Society*. 2019;67:2560-2567.
- 387 7. Sniderman AD, Islam S, McQueen M, Pencina M, Furberg CD, Thanassoulis G

- 388 and Yusuf S. Age and Cardiovascular Risk Attributable to Apolipoprotein B,
389 Low-Density Lipoprotein Cholesterol or Non-High-Density Lipoprotein Cholesterol.
390 *Journal of the American Heart Association*. 2016;5.
- 391 8. Iversen A, Jensen JS, Scharling H and Schnohr P. Hypercholesterolaemia and risk
392 of coronary heart disease in the elderly: impact of age: the Copenhagen City Heart
393 Study. *European journal of internal medicine*. 2009;20:139-44.
- 394 9. Bowman K, Delgado J, Henley WE, Masoli JA, Kos K, Brayne C, Thokala P,
395 Lafortune L, Kuchel GA, Ble A and Melzer D. Obesity in Older People With and
396 Without Conditions Associated With Weight Loss: Follow-up of 955,000 Primary
397 Care Patients. *The journals of gerontology Series A, Biological sciences and medical*
398 *sciences*. 2017;72:203-209.
- 399 10. Li H, Ma J, Zheng D, Li X, Guo X, Wang J and Su P. Sex differences in the
400 non-linear association between BMI and LDL cholesterol in middle-aged and older
401 adults: findings from two nationally representative surveys in China. *Lipids Health*
402 *Dis*. 2021;20:162.
- 403 11. Palmer LJ. UK Biobank: bank on it. *Lancet (London, England)*.
404 2007;369:1980-1982.
- 405 12. Fry D, Almond R, Moffat S, Gordon M, Singh P. Companion Document to
406 Accompany Serum Biomarker Data [Internet]. UK Biobank Biomarker Project. 2019
407 [cited 2020 Feb 4]. Available from:
408 https://biobank.ndph.ox.ac.uk/showcase/showcase/docs/serum_biochemistry.pdf.
- 409 13. Elliott P and Peakman TC. The UK Biobank sample handling and storage

- 410 protocol for the collection, processing and archiving of human blood and urine.
- 411 *International journal of epidemiology*. 2008;37:234-44.
- 412 14. Jarman B, Townsend P and Carstairs V. Deprivation indices. *BMJ (Clinical*
- 413 *research ed)*. 1991;303:523.
- 414 15. The IPAQ Group. IPAQ scoring protocol - International Physical Activity
- 415 Questionnaire. <https://sites.google.com/site/theipaq/scoring-protocol>.
- 416 16. Ainsworth BE, Haskell WL, Whitt MC, Irwin ML, Swartz AM, Strath SJ,
- 417 O'Brien WL, Bassett DR, Jr., Schmitz KH, Emplaincourt PO, Jacobs DR, Jr. and Leon
- 418 AS. Compendium of physical activities: an update of activity codes and MET
- 419 intensities. *Medicine and science in sports and exercise*. 2000;32:S498-504.
- 420 17. Ford ES. Prevalence of the metabolic syndrome defined by the International
- 421 Diabetes Federation among adults in the U.S. *Diabetes care*. 2005;28:2745-9.
- 422 18. Greenland S. Dose-response and trend analysis in epidemiology: alternatives to
- 423 categorical analysis. *Epidemiology*. 1995;6:356-65.
- 424 19. Flegal KM, Kit BK, Orpana H and Graubard BI. Association of all-cause
- 425 mortality with overweight and obesity using standard body mass index categories: a
- 426 systematic review and meta-analysis. *Jama*. 2013;309:71-82.
- 427 20. Li R and Chambless L. Test for additive interaction in proportional hazards
- 428 models. *Ann Epidemiol*. 2007;17:227-36.
- 429 21. Reeder BA, Angel A, Ledoux M, Rabkin SW, Young TK and Sweet LE. Obesity
- 430 and its relation to cardiovascular disease risk factors in Canadian adults. Canadian
- 431 Heart Health Surveys Research Group. *CMAJ : Canadian Medical Association*

- 432 *journal = journal de l'Association medicale canadienne*. 1992;146:2009-19.
- 433 22. Varbo A, Benn M, Smith GD, Timpson NJ, Tybjaerg-Hansen A and Nordestgaard
434 BG. Remnant cholesterol, low-density lipoprotein cholesterol, and blood pressure as
435 mediators from obesity to ischemic heart disease. *Circulation research*.
436 2015;116:665-73.
- 437 23. Orkaby AR, Gaziano JM, Djousse L and Driver JA. Statins for Primary
438 Prevention of Cardiovascular Events and Mortality in Older Men. *Journal of the*
439 *American Geriatrics Society*. 2017;65:2362-2368.
- 440 24. Orkaby AR, Driver JA, Ho YL, Lu B, Costa L, Honerlaw J, Galloway A, Vassy
441 JL, Forman DE, Gaziano JM, Gagnon DR, Wilson PWF, Cho K and Djousse L.
442 Association of Statin Use With All-Cause and Cardiovascular Mortality in US
443 Veterans 75 Years and Older. *Jama*. 2020;324:68-78.
- 444 25. Hawley CE, Roefaro J, Forman DE and Orkaby AR. Statins for Primary
445 Prevention in Those Aged 70 Years and Older: A Critical Review of Recent
446 Cholesterol Guidelines. *Drugs & aging*. 2019;36:687-699.
- 447 26. Karlsson IK, Lehto K, Gatz M, Reynolds CA and Dahl Aslan AK. Age-dependent
448 effects of body mass index across the adult life span on the risk of dementia: a cohort
449 study with a genetic approach. *BMC medicine*. 2020;18:131.
- 450 27. Lu Y, Hajifathalian K, Ezzati M, Woodward M, Rimm EB and Danaei G.
451 Metabolic mediators of the effects of body-mass index, overweight, and obesity on
452 coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with
453 1.8 million participants. *Lancet (London, England)*. 2014;383:970-83.

454 28. Kim SY, Go TH, Lee JH, Moon JS, Kang DR, Bae SJ, Kim SE, Lee SJ, Cho DH,
455 Park YJ, Youn YJ, Kim JY and Ahn SG. Differential association of metabolic
456 syndrome and low-density lipoprotein cholesterol with incident cardiovascular disease
457 according to sex among Koreans: a national population-based study. *European*
458 *journal of preventive cardiology*. 2022;28:2021-2029.
459

460 **Figure legends:**

461 **Figure 1.** Association of LDL cholesterol or body mass index with risk of coronary
462 heart disease via restricted cubic spline regression (four knots). *Adjusted for age, sex,
463 ethnicity, education, smoking, passive smoking, alcohol intake frequency, physical
464 activity, Townsend deprivation index, metabolic disorders, lipid lowering drugs and
465 body mass index or LDL cholesterol.

466 **Figure 2.** Association of LDL cholesterol or body mass index with risk of coronary
467 heart disease across age groups via restricted cubic spline regression (four knots).
468 *Adjusted for age, sex, ethnicity, education, smoking, passive smoking, alcohol intake
469 frequency, physical activity, Townsend deprivation index, metabolic disorders, lipid
470 lowering drugs and body mass index or LDL cholesterol.

471 **Figure 3:** Association of LDL cholesterol or body mass index with risk of coronary
472 heart disease across increasing age via Cox proportional hazards model. *Adjusted for
473 age, sex, ethnicity, education, smoking, passive smoking, alcohol intake frequency,
474 physical activity, Townsend deprivation index, metabolic disorders, lipid lowering
475 drugs and body mass index or LDL cholesterol.

476 **Figure 4:** Stratified analyses for the association of LDL cholesterol or body mass
477 index with risk of coronary heart disease across age groups via Cox proportional
478 hazards model. *Adjusted for age, sex, ethnicity, education, smoking, passive
479 smoking, alcohol intake frequency, physical activity, Townsend deprivation index,
480 metabolic disorders, lipid lowering drugs and body mass index or LDL cholesterol.

481

Table 1. Baseline information of the study population across age groups.

Variables	Study population (N=368274)	<50 years (N=84717)	50-54 years (N=56544)	55-59 years (N=65680)	60-64 years (N=87263)	>=65 years (N=74070)	P value
Age	56.7±8.1	45.2±2.6	52.1±1.4	57.1±1.4	62±1.4	67.1±1.6	<0.001
LDL Cholesterol, mmol/L	3.6±0.8	3.4±0.8	3.6±0.8	3.7±0.8	3.7±0.9	3.6±0.9	<0.001
Body mass index, kg/m ²	27.3±4.7	26.9±4.9	27.3±4.9	27.4±4.8	27.4±4.6	27.4±4.3	<0.001
Townsend deprivation index	-1.4±3	-0.9±3.2	-1.2±3.1	-1.4±3	-1.6±2.9	-1.6±2.9	<0.001
Summed MET, min/week	2668±2718	2660.7±2769.7	2569.4±2719.2	2538.7±2691.5	2706.4±2693.2	2829.1±2696.5	<0.001
Sex							<0.001
Female	202853(55.1)	45922(54.2)	31962(56.5)	37048(56.4)	48783(55.9)	39138(52.8)	
Male	165421(44.9)	38795(45.8)	24582(43.5)	28632(43.6)	38480(44.1)	34932(47.2)	
Ethnicity							<0.001
British	324425(88.1)	69723(82.3)	48715(86.2)	58283(88.7)	79975(91.6)	67729(91.4)	
Others	43849(11.9)	14994(17.7)	7829(13.8)	7397(11.3)	7288(8.4)	6341(8.6)	
Education							<0.001
College or University degree	121308(32.9)	33372(39.4)	20958(37.1)	23554(35.9)	25834(29.6)	17590(23.7)	
A levels/AS levels or equivalent	41605(11.3)	11586(13.7)	7516(13.3)	7785(11.9)	8639(9.9)	6079(8.2)	
O levels/GCSEs or equivalent	79500(21.6)	19824(23.4)	11953(21.1)	13166(20)	18968(21.7)	15589(21)	
CSEs or equivalent	20785(5.6)	8704(10.3)	4737(8.4)	3660(5.6)	2453(2.8)	1231(1.7)	
NVQ or equivalent	23660(6.4)	4151(4.9)	3627(6.4)	4642(7.1)	6419(7.4)	4821(6.5)	
Other professional qualifications	18785(5.1)	2118(2.5)	2107(3.7)	3430(5.2)	5681(6.5)	5449(7.4)	
Unknown	62631(17)	4962(5.9)	5646(10)	9443(14.4)	19269(22.1)	23311(31.5)	
Smoking							<0.001
Never	203911(55.4)	51766(61.1)	33515(59.3)	36140(55)	45370(52)	37120(50.1)	
Previous	124601(33.8)	20813(24.6)	16121(28.5)	22578(34.4)	33955(38.9)	31134(42)	
Current	37998(10.3)	11785(13.9)	6702(11.9)	6688(10.2)	7497(8.6)	5326(7.2)	

Unknown	1764(0.5)	353(0.4)	206(0.4)	274(0.4)	441(0.5)	490(0.7)	
Passive smoking							<0.001
No	322151(87.5)	71988(85)	48725(86.2)	57536(87.6)	77708(89.1)	66194(89.4)	
Yes	46123(12.5)	12729(15)	7819(13.8)	8144(12.4)	9555(10.9)	7876(10.6)	
Alcohol intake frequency							<0.001
Daily	75829(20.6)	12803(15.1)	10445(18.5)	14162(21.6)	20596(23.6)	17823(24.1)	
Often	180605(49)	44256(52.2)	29248(51.7)	32753(49.9)	41565(47.6)	32783(44.3)	
Seldom	82719(22.5)	20912(24.7)	12682(22.4)	13973(21.3)	18454(21.1)	16698(22.5)	
Never	28341(7.7)	6510(7.7)	4041(7.1)	4667(7.1)	6511(7.5)	6612(8.9)	
Unknown	780(0.2)	236(0.3)	128(0.2)	125(0.2)	137(0.2)	154(0.2)	
Metabolic disorder							
Hypertension	237905(64.6)	38136(10.4)	32477(8.8)	42877(65.3)	64124(73.5)	60291(81.4)	<0.001
Hyperglycemia/diabetes	59777(16.2)	9170(2.5)	7578(2.1)	10562(16.1)	16207(18.6)	16260(22)	<0.001
Hypertriglyceridemia	145646(39.5)	28048(7.6)	21298(5.8)	26693(40.6)	37539(43)	32068(43.3)	<0.001
Low HDL Cholesterol	74743(20.3)	20459(5.6)	11467(3.1)	12254(18.7)	16380(18.8)	14183(19.1)	<0.001
Use of lipid lowering drugs	51240(13.9)	3082(0.8)	4360(1.2)	8032(12.2)	16337(18.7)	19429(26.2)	<0.001

Table 2. Association of LDL cholesterol or body mass index with risk of coronary heart disease across age groups.

Age	Number of individuals	Number of outcomes	Follow up years	IR, per 1000 person years	LDL cholesterol		Body mass index	
					Age and sex adjusted	Multivariable adjusted ^a	Age and sex adjusted	Multivariable adjusted ^a
Overall	368274	26947	4595322	5.86	1.04(1.02,1.05)	1.16(1.14,1.18)	1.31(1.29,1.32)	1.14(1.12,1.16)
<50	84717	2524	1099075	2.30	1.38(1.32,1.44)	1.35(1.29,1.41)	1.46(1.40,1.51)	1.15(1.10,1.20)
50-54	56544	2746	723131	3.80	1.18(1.13,1.23)	1.26(1.20,1.31)	1.33(1.28,1.38)	1.11(1.07,1.16)
55-59	65680	4361	827492	5.27	1.06(1.03,1.10)	1.19(1.15,1.24)	1.31(1.28,1.35)	1.12(1.08,1.16)
60-64	87263	7928	1071790	7.40	0.99(0.96,1.01)	1.11(1.08,1.14)	1.28(1.25,1.31)	1.13(1.10,1.16)
>=65	74070	9388	873834	10.74	0.94(0.92,0.96)	1.08(1.05,1.11)	1.27(1.24,1.30)	1.15(1.12,1.17)
P heterogeneity					<0.001	<0.001	<0.001	<0.001

^a Adjusted for age, sex, birth country, education, smoking, passive smoking, alcohol intake frequency, physical activity, Townsend deprivation index, metabolic disorders, lipid lowering drugs and body mass index or LDL cholesterol.

Table 3. Mediation of LDL cholesterol or body mass index between body mass index or LDL cholesterol and risk of coronary heart disease across age groups.

Age	LDL cholesterol			Body mass index		
	Confounders adjusted ^a	Confounders and BMI adjusted ^b	The percentage of excess risk mediated	Confounders adjusted ^a	Confounders and LDLc adjusted ^b	The percentage of excess risk mediated
Overall	1.16(1.15,1.18)	1.16(1.14,1.18)	0%	1.14(1.13,1.16)	1.14(1.12,1.16)	0%
<50	1.36(1.30,1.42)	1.35(1.29,1.41)	2.78%	1.17(1.12,1.21)	1.15(1.10,1.20)	11.76%
50-54	1.26(1.20,1.32)	1.26(1.20,1.31)	0%	1.12(1.08,1.17)	1.11(1.07,1.16)	8.33%
55-59	1.19(1.15,1.24)	1.19(1.15,1.24)	0%	1.12(1.09,1.16)	1.12(1.08,1.16)	0%
60-64	1.11(1.08,1.14)	1.11(1.08,1.14)	0%	1.13(1.10,1.16)	1.13(1.10,1.16)	0%
>=65	1.07(1.05,1.10)	1.08(1.05,1.11)	-	1.15(1.12,1.17)	1.15(1.12,1.17)	0%

^a Adjusted for age, sex, ethnicity, education, smoking, passive smoking, alcohol intake frequency, physical activity, Townsend deprivation index, metabolic disorders, lipid lowering drugs;

^b Adjusted for age, sex, ethnicity, education, smoking, passive smoking, alcohol intake frequency, physical activity, Townsend deprivation index, metabolic disorders, lipid lowering drugs and body mass index or LDL cholesterol.

Table 4. Interaction between LDL cholesterol and body mass index on the risk of coronary heart disease across age groups.

Age	Adjusted HR(95%CI) ^a				Relative excess risk of interaction	P for multiplicative interaction ^a
	None	Increased body mass index	Increased LDL cholesterol	Both increased		
Overall	Ref	1.19(1.14,1.25)	1.27(1.20,1.34)	1.49(1.43,1.56)	0.03	0.688
<50	Ref	1.31(1.12,1.53)	1.57(1.31,1.87)	2.06(1.78,2.39)	0.18	0.981
50-54	Ref	1.02(0.88,1.19)	1.24(1.05,1.46)	1.51(1.31,1.74)	0.25	0.067
55-59	Ref	1.10(0.97,1.24)	1.24(1.09,1.42)	1.42(1.27,1.60)	0.08	0.559
60-64	Ref	1.17(1.07,1.27)	1.17(1.06,1.29)	1.41(1.29,1.53)	0.07	0.563
>=65	Ref	1.23(1.14,1.32)	1.17(1.07,1.28)	1.31(1.21,1.42)	-0.09	0.070

^a Adjusted for age, sex, ethnicity, education, smoking, passive smoking, alcohol intake frequency, physical activity, Townsend deprivation index, metabolic disorders and lipid lowering drugs.







